TQB2450 with anlotinib shows promise in STS
TQB2450 combined with anlotinib showed promising activity in patients with alveolar soft part sarcoma (ASPS), according to results from a phase 2 study.
In this single-arm study, 30 patients with locally advanced or metastatic soft tissue sarcoma (LA/M STS) previously unresponsive to ≥1chemotherapy regimen were administered anlotinib orally from day 1 to day 14 every 3 weeks and TQB2450 by intravenous infusion on day 1 every 3 weeks.
The objective response rate (ORR) was 36.67%, the disease control rate (DCR) was 76.67%, and the median progression-free survival (PFS) was 7.85 months. The median overall survival was not reached
Forty percent (12/30) of participants had ASPS. Amongst these patients, the ORR was 75% and the median PFS was 23.06 months.
The most common treatment-related adverse events were hypothyroidism (76.67%), hypertriglyceridemia (63.33%), hypercholesterolemia (60.00%), and elevated blood lactate dehydrogenase (53.33%).
Liu J, Gao T, Tan Z, et al. Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma. Clin Cancer Res. 2022;10:13:03.583. doi: 10.1158/1078-0432.CCR-22-0871. Epub ahead of print. PMID: 35675031.